Form 4: Zimmer Biomet VP Controller Reports Stock Transactions

Zimmer Biomet's VP, Controller, and CAO, Paul A. Stellato, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Summary

• Paul A. Stellato, VP, Controller, and CAO of Zimmer Biomet Holdings, Inc., reported transactions involving the company's common stock.
• On September 1, 2025, Stellato acquired 1,281 shares of common stock through the exercise/conversion of restricted stock units (RSUs) at a price of $0.
• Concurrently, 402 shares were disposed of at a price of $105.6 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Stellato directly beneficially owns 3,710 shares of Zimmer Biomet common stock.
• The reported beneficial ownership also includes 59 shares acquired under the Employee Stock Purchase Plan on June 30, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing reports a routine executive compensation event (RSU vesting) which is generally positive as it aligns executive interests with shareholders. The disposition for tax purposes is standard and not indicative of negative sentiment.

Positives

• Vesting of Restricted Stock Units indicates a compensation event for a key executive, aligning management interests with shareholder value.
• The executive's continued beneficial ownership of 3,710 shares demonstrates an ongoing stake in the company.

Negatives

• Disposition of 402 shares for tax withholding purposes reduces the executive's direct shareholding, though this is a common and expected practice for RSU vesting.

Future Outlook

NA

Industry Context

This is a routine executive compensation event and does not directly relate to broader industry trends or competitors, other than reflecting standard executive compensation practices in the medical device industry.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting executive compensation and tax-related transactions, which is common practice across publicly traded companies in all industries, including medical device companies like Stryker (SYK) or Johnson & Johnson (JNJ).
• The specific RSU vesting and tax withholding mechanism is a widely adopted compensation structure for executives.

Stakeholder Impact

• Shareholders: Minor positive impact due to executive's continued equity stake and alignment of interests.
• Employees: No direct impact beyond the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and subsequent tax-related share disposition. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are standard and expected for an executive receiving equity compensation, thus maintaining a 'hold' recommendation based solely on this filing.

Keywords

Zimmer Biomet, ZBH, Paul A. Stellato, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Transaction, Executive Compensation, Beneficial Ownership